TY  - JOUR
AU  - Montalbán, Carlos
AU  - Díaz-López, Antonio
AU  - Dlouhy, Ivan
AU  - Rovira, Jordina
AU  - Lopez-Guillermo, Armando
AU  - Alonso, Sara
AU  - Martín, Alejandro
AU  - Sancho, Juan M
AU  - García, Olga
AU  - Sánchez, Jose M
AU  - Rodríguez, Mario
AU  - Novelli, Silvana
AU  - Salar, Antonio
AU  - Gutiérrez, Antonio
AU  - Rodríguez-Salazar, Maria J
AU  - Bastos, Mariana
AU  - Domínguez, Juan F
AU  - Fernández, Rubén
AU  - Gonzalez de Villambrosia, Sonia
AU  - Queizan, José A
AU  - Córdoba, Raul
AU  - de Oña, Raquel
AU  - López-Hernandez, Andrés
AU  - Freue, Julian M
AU  - Garrote, Heidys
AU  - López, Lourdes
AU  - Martin-Moreno, Ana M
AU  - Rodriguez, Jose
AU  - Abraira, Víctor
AU  - García, Juan F
AU  - GELTAMO-IPI Project Investigators
PY  - 2017
DO  - 10.1111/bjh.14489
UR  - http://hdl.handle.net/10668/10794
T2  - British journal of haematology
AB  - The study included 1848 diffuse large B-cell lymphoma (DLBCL)patients treated with chemotherapy/rituximab. The aims were to validate the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and explore the effect of adding...
LA  - en
KW  - DLBCL
KW  - prognostic scores
KW  - risk assessment
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Remission Induction
KW  - Reproducibility of Results
KW  - Treatment Outcome
KW  - beta 2-Microglobulin
TI  - Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.
TY  - research article
VL  - 176
ER  -